| 摘要 |
A process for reducing in a primate recipient a natural antibody response against a graft from a non-primate donor, comprising administering to said recipient an effective amount of a carrier linked to one or more galactosyl-alpha-1,3-galactose moieties is disclosed, along with additional optional processes involving use of immunosuppressive agents and hematopoietic stem cells. |
